Get the Stockscreener App
16.64
0.24%
0.04
After Hours:
16.41
-0.23
-1.38%
Theravance Biopharma Inc stock is traded at $16.64, with a volume of 349.32K.
It is up +0.24% in the last 24 hours and up +20.75% over the past month.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
See More
Previous Close:
$16.60
Open:
$16.66
24h Volume:
349.32K
Relative Volume:
0.58
Market Cap:
$856.84M
Revenue:
$107.46M
Net Income/Loss:
$105.90M
P/E Ratio:
8.2067
EPS:
2.0276
Net Cash Flow:
$238.50M
1W Performance:
+0.24%
1M Performance:
+20.75%
6M Performance:
+19.71%
1Y Performance:
+92.82%
1-Day Range:
$16.40
$16.80
1-Week Range:
$16.21
$16.99
52-Week Range:
$8.33
$21.03
Theravance Biopharma Inc Stock (TBPH) Company Profile
Name
Theravance Biopharma Inc
Sector
Industry
Phone
650-808-6000
Address
UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN
Compare TBPH vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TBPH
Theravance Biopharma Inc
|
16.64 | 854.78M | 107.46M | 105.90M | 238.50M | 2.0276 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-05-26 | Downgrade | Oppenheimer | Outperform → Perform |
| Mar-04-26 | Downgrade | B. Riley Securities | Buy → Neutral |
| Dec-03-25 | Initiated | Oppenheimer | Outperform |
| Sep-12-25 | Initiated | B. Riley Securities | Buy |
| Aug-06-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Apr-12-24 | Initiated | BTIG Research | Buy |
| Jan-08-24 | Downgrade | Evercore ISI | Outperform → In-line |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Nov-05-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Sep-15-21 | Downgrade | JP Morgan | Overweight → Underweight |
| Aug-25-21 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Aug-24-21 | Downgrade | Cowen | Outperform → Market Perform |
| Oct-14-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-07-20 | Initiated | JP Morgan | Overweight |
| Jun-15-20 | Initiated | Morgan Stanley | Equal-Weight |
| May-13-20 | Initiated | Cowen | Outperform |
| Jan-08-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-06-19 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Oct-29-19 | Initiated | H.C. Wainwright | Buy |
| Mar-29-18 | Resumed | Piper Jaffray | Overweight |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jun-16-17 | Initiated | Cantor Fitzgerald | Overweight |
| May-11-17 | Reiterated | Needham | Buy |
| Dec-21-16 | Initiated | Needham | Buy |
| Nov-03-16 | Initiated | Piper Jaffray | Overweight |
| Oct-12-16 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Aug-03-16 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jun-20-16 | Initiated | Guggenheim | Buy |
| Jun-20-16 | Reiterated | Leerink Partners | Outperform |
| May-12-16 | Initiated | Leerink Partners | Outperform |
| May-05-16 | Downgrade | BofA/Merrill | Buy → Neutral |
| Feb-03-15 | Upgrade | Robert W. Baird | Underperform → Neutral |
View All
Theravance Biopharma Inc Stock (TBPH) Latest News
Bronstein, Gewirtz & Grossman, LLC Encourages Theravance Biopharma, Inc. (TBPH) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Theravance Biopharma (TBPH) price target decreased by 39.48% to 16.49 - MSN
2026-04-14 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Theravance Biopharma, Inc. (TBPH) and Encourages Investors to Learn More About the Investigation | NDAQ:TBPH | Press Release - Stockhouse
Theravance Biopharma, Inc. (TBPH) Investigation: Bronstein, Gewir - The National Law Review
Risk Report: Is Theravance Biopharma Inc a cyclical or defensive stockPortfolio Return Summary & Verified Chart Pattern Signals - baoquankhu1.vn
2026-04-12 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Theravance Biopharma, Inc. (TBPH) And Encourages Stockholders to Reach Out | NDAQ:TBPH | Press Release - Stockhouse
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc.TBPH - PR Newswire
Theravance's Q4 earnings and revenues miss estimates - MSN
TBPH Investors Have Opportunity to Join Theravance Biopharma, Inc. Fraud Investigation with the Schall Law Firm - GlobeNewswire
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX) and Theravance Biopharma (TBPH) - The Globe and Mail
TBPH: B. Riley Securities Raises Price Target to $17.00, Maintai - GuruFocus
B. Riley Raises Price Target on Theravance Biopharma to $17 From $14, Keeps Neutral Rating - marketscreener.com
Zacks Industry Outlook Features Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics, and Avalo Therapeutics - Bitget
Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo Therapeutics - Zacks Investment Research
Theravance Biopharma (NASDAQ:TBPH) Lowered to "Buy" Rating by Wall Street Zen - MarketBeat
JPMorgan Chase & Co. Purchases 93,591 Shares of Theravance Biopharma, Inc. $TBPH - marketbeat.com
Theravance Biopharma (TBPH) CEO awarded 75,000 Ordinary Shares - Stock Titan
Theravance Biopharma (TBPH) CFO receives 37,500-share equity grant in Form 4 - Stock Titan
Theravance Biopharma (TBPH) SVP receives 37,500-share equity grant - Stock Titan
Theravance Biopharma (TBPH) SVP awarded 18,750 shares in Form 4 filing - Stock Titan
Multiple System Atrophy Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Ionis Pharma, Biohaven Pharma, Lundbeck A/S, Alterity Therapeutics, Theravance Biopharma, Brain Neuro - Barchart.com
TBPH PE Ratio & Valuation, Is TBPH Overvalued - Intellectia AI
How Theravance Biopharma Inc. (TBPH) Affects Rotational Strategy Timing - Stock Traders Daily
Tudor Investment Corp ET AL Decreases Stake in Theravance Biopharma, Inc. $TBPH - MarketBeat
Theravance Biopharma Hits Day Low of $13.08 Amid Price Pressure - Markets Mojo
Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Big Picture: Can Theravance Biopharma Inc sustain its profitabilityLayoff News & Daily Profit Focused Screening - baoquankhu1.vn
Theravance Secures Long-Term YUPELRI Patent Litigation Settlement - TipRanks
Theravance Biopharma Inc. (TBPH) has disclosed that a settlement agreement has been filed with the U.S. Securities and Exchange Commission (SEC), and is currently under review by the Department of Justice and the Federal Trade Commission. - Bitget
Theravance (NASDAQ: TBPH) sets 2039 generic date in YUPELRI patent settlement - Stock Titan
Theravance Biopharma (NASDAQ:TBPH) Raised to "Strong-Buy" at Wall Street Zen - MarketBeat
Theravance Biopharma SEC Filing: Exhibits, Documents, and XBRL Taxonomy Reference Table - Minichart
TBPH Guided for $75M in Milestones While Trial Risk Went Unquantified -- LEVI & KORSINSKY, LLP - GlobeNewswire
Weiss Asset Management (TBPH) details 7.46M-share, 14.5% Theravance Biopharma stake - Stock Titan
Theravance drops rare disease drug after late-stage trial setback - MSN
Theravance Biopharma (NASDAQ:TBPH) Stock Price Expected to Rise, TD Cowen Analyst Says - MarketBeat
TBPH: Today's Rating Maintained by TD Cowen with Raised Price Ta - GuruFocus
TD Cowen raises Theravance Biopharma stock price target on cash flow focus - Investing.com Canada
Theravance Biopharma 2025 Annual Report: YUPELRI Commercialization, Strategic Review, and Organizational Restructuring - Minichart
Theravance Biopharma 2025 10-K: $107.5M Revenue, $105.9M Net Income - tradingview.com
Theravance Biopharma (NASDAQ: TBPH) restructures after ampreloxetine flop and royalty sale - Stock Titan
Here's why Theravance Biopharma (TBPH) is a strong growth stock - MSN
(TBPH) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Theravance Biopharma (NASDAQ:TBPH) Raised to "Strong-Buy" at Zacks Research - MarketBeat
Theravance Biopharma (NASDAQ:TBPH) Stock Rating Lowered by Wall Street Zen - MarketBeat
Theravance's Q4 Earnings and Revenues Miss Estimates - TradingView
Theravance Biopharma Inc Stock (TBPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):